HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sequestration Kicks In: FDA Will Manage For Now, But Could Suffer Aftereffects

This article was originally published in The Rose Sheet

Executive Summary

With the implementation of across-the-board spending cuts, FDA will be unable to add the hundreds of new employees needed to meet the goals of user-fee and other programs, a paucity that could damage the agency for years to come.

You may also be interested in...



Hamburg Details Some Sequestration Impact On FDA

Commissioner says allowing the sequester would slow implementation of FDASIA provisions and reduce some overseas inspections.

Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

In-Person US FDA Meetings Returning? Agency Will Support Those Events At HQ

A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.

Latest News
See All
UsernamePublicRestriction

Register

RS018441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel